Antibody-Dependent Cellular Cytotoxicity (ADCC)
NK cells play a pivotal role in innate immune responses, targeting cells marked by antibodies, such as tumor cells. Within the ADCC mechanism, antibodies bind to tumor cell antigens and come into contact with the activating Fc receptors of NK cells, thereby triggering their cytotoxic activity.
Target Cell Selection
• Tumor Cell Lines: Suitable for a wide range of research and testing needs.
• Primary Tumor Cells: More accurately simulating biological environments.
• Genetically Engineered Cell Lines: Customized through genetic technology to meet specific research demands.
Effector Cell Sources
• Commercially-sourced PBMCs: Standardized, suitable for most research.
• Clinically-derived PBMCs: More targeted, suitable for specific scenarios.
• NK92 Cell Line: Specially designed for NK cell research.
Analysis & Detection
• Flow Cytometry: High precision differentiation of effector-target cells, providing accurate data for research.
• Apoptotic Cell Percentage: Utilizing flow cytometry to accurately calculate the proportion of apoptotic cells, offering a direct assessment of ADCC effects.
Conclusion
Our ADCC platform offers a comprehensive set of research tools. Whether you're selecting the right cell source or conducting precise analysis and detection, we've got you covered. Begin your exploration of the potential role of ADCC in tumor therapy with us.

Validate the in vitro ADCC activity of Rituximab on Raji cells (with NK92 as effector cells).